GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Cyclically Adjusted Price-to-FCF

Egetis Therapeutics AB (OSTO:PLED BTA) Cyclically Adjusted Price-to-FCF : (As of Jun. 29, 2025)


View and export this data going back to . Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Egetis Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Egetis Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-2.438/132.8245*132.8245
=-2.438

Current CPI (Mar. 2025) = 132.8245.

Egetis Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.658 99.995 -0.874
201509 -0.377 100.228 -0.500
201512 -0.328 100.276 -0.434
201603 -0.245 100.751 -0.323
201606 -0.441 101.019 -0.580
201609 -0.296 101.138 -0.389
201612 -0.343 102.022 -0.447
201703 -0.438 102.022 -0.570
201706 -0.719 102.752 -0.929
201709 -0.352 103.279 -0.453
201712 -1.664 103.793 -2.129
201803 -0.557 103.962 -0.712
201806 -1.001 104.875 -1.268
201809 -0.614 105.679 -0.772
201812 -0.739 105.912 -0.927
201903 0.985 105.886 1.236
201906 -1.003 106.742 -1.248
201909 -1.314 107.214 -1.628
201912 -1.053 107.766 -1.298
202003 -1.361 106.563 -1.696
202006 -1.237 107.498 -1.528
202009 -0.900 107.635 -1.111
202012 -1.431 108.296 -1.755
202103 -1.286 108.360 -1.576
202106 -1.401 108.928 -1.708
202109 -1.136 110.338 -1.368
202112 -0.957 112.486 -1.130
202203 -1.217 114.825 -1.408
202206 -1.294 118.384 -1.452
202209 -1.566 122.296 -1.701
202212 -2.288 126.365 -2.405
202303 -2.915 127.042 -3.048
202306 -2.354 129.407 -2.416
202309 -3.413 130.224 -3.481
202312 -1.525 131.912 -1.536
202403 -2.031 132.205 -2.041
202406 -2.068 132.716 -2.070
202409 -2.291 132.304 -2.300
202412 -1.965 132.987 -1.963
202503 -2.438 132.825 -2.438

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Egetis Therapeutics AB  (OSTO:PLED BTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines